INOVIO PHARMACEUTICALS, INC. - 8-K Filing
Inovio reports Q3 2026 net loss of $49.2 million and announces FDA accelerated approval for VOCERYQ (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $INO
Read the full article at SEC EDGAR
Part of the story Noble Corp plc - 8-K Filing (63 articles)